2 not yet recruiting, 1 recruiting. 2 Phase 1, 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Not yet recruiting 2 |
| Phase 2 | 2 | Not yet recruiting 2 |
| Not applicable | 1 | Recruiting 1 |
Follow Cilcare SAS: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have Difficulty Understanding Speech in Noisy Situations CIL001 (Paliroden), Placebo - Cochlear Synaptopathy | Phase 1 / Phase 2 | Not yet recruiting | Cilcare SAS | 135 | 2027-01-01 | 2026-10-26 |
| A Study Testing Safety and Efficacy of Transtympanic Paliroden for the Treatment of Cochlear Synaptopathy in Participants With Chronic, Constant Tinnitus paliroden (CIL001), Placebo - Tinnitus, Bilateral, Cochlear Synaptopathy | Phase 1 / Phase 2 | Not yet recruiting | Cilcare SAS | 60 | 2027-01-01 | 2026-09-17 |
| Early Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR) Thorough Hearing assessment - Mild Cognitive Impairment (MCI) Amnestic, Parkinson Disease (PD) | Not applicable | Recruiting | Cilcare SAS | 309 | 2025-03-24 | 2025-12-09 |
Hearing Loss, Hidden (2) · Cognitive Dysfunction (1) · Diabetes Mellitus (1) · Parkinson Disease (1) · Tinnitus (1)
France (1)
2025 (1)